No Data
No Data
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $19
H.C. Wainwright analyst Robert Burns maintains $Cogent Biosciences(COGT.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success rate of 24.0
Express News | Needham Reiterates Buy on Cogent Biosciences, Maintains $18 Price Target
Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $18
Needham analyst Ami Fadia maintains $Cogent Biosciences(COGT.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 44.4% and a tot
Express News | Cogent Biosciences Reveals Additional Data From Part 1 Of Its Ongoing SUMMIT Clinical Trial Evaluating The Selective KIT D816V Inhibitor, Bezuclastinib, In Patients With Nonadvanced Systemic Mastocytosis
Express News | Cogent Biosciences Inc: Recommended Dose of 100 Mg Demonstrates a Favorable Safety and Tolerability Profile
Express News | Cogent Biosciences Inc: Summit Trial Showed Clinically Meaningful Improvement in Skin Symptoms as Well as Objective Reduction in Skin Lesions
No Data